Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

NTLA / Intellia Therapeutics, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 3 (Activist Investment)

2018-02-16 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)*   INTELLIA THERAPEUTICS, INC. (Name of Issuer)     COMMON STOCK (Title of Class of Securities)   45826J105 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP V LLC OrbiMed Global Healthcare GP LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone:  (212) 739-6400 (Name, Address and Telephone Number of Person Authorized to Receive No

NTLA / Intellia Therapeutics, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 3 (Activist Investment)

2018-02-16 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)*   INTELLIA THERAPEUTICS, INC. (Name of Issuer)     COMMON STOCK (Title of Class of Securities)   45826J105 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP V LLC OrbiMed Global Healthcare GP LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone:  (212) 739-6400 (Name, Address and Telephone Number of Person Authorized to Receive No

U.S. Biotech/Pharma Sector Daily Observations Letter: February 15, 2018

2018-02-16 seekingalpha
Arrowhead Pharmaceuticals stock was up >6% after receiving FDA Orphan drug designation for its RNAi therapy to treat alpha-1 antitrypsin deficiency. (29-1)

ARK Innovation ETF: Invest In Cutting-Edge Stocks

2018-02-15 seekingalpha
If you are looking for an investment that gives you exposure to cutting-edge, innovative companies, then the ARK Innovation ETF (ARKK) is something to consider. ARK is a collection of 56 innovative companies. Many of them are household names, but some are less well-known. (77-0)

NTLA / Intellia Therapeutics, Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 2 INTELLIA THERAPEUTICS INC COMMON STOCK Cusip #45826J105 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #45826J105 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,781,232 Item 6: 0 Item 7: 4,286,577 Item 8: 0 Item 9: 4,286,577 Item 11: 10.

NTLA / Intellia Therapeutics, Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 2 INTELLIA THERAPEUTICS INC COMMON STOCK Cusip #45826J105 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #45826J105 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,781,232 Item 6: 0 Item 7: 4,286,577 Item 8: 0 Item 9: 4,286,577 Item 11: 10.

Does The ARK Innovation ETF Reach Too Far?

2018-02-12 seekingalpha
A few weeks ago Seeking Alpha published a list of some investments which had a good following but for whatever reason did not have any coverage in a long time. In that list there were a number of exchange traded funds which peaked my interest, one in particular is the ARK Innovation ETF (ARKK). (16-0)

NTLA / Intellia Therapeutics, Inc. / Atlas Venture Fund IX, L.P. - SC 13G/A (Passive Investment)

2018-02-12 sec.gov
    UNITED STATES     SECURITIES AND EXCHANGE COMMISSION     Washington, D.C. 20549         SCHEDULE 13G (Rule 13d-102)   Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1)*   INTELLIA THERAPUTICS, INC. (Name of Issuer) Common Stock, $0.0001 (Title of Class of Securities) 45826J105 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi

NTLA / Intellia Therapeutics, Inc. / Atlas Venture Fund IX, L.P. - SC 13G/A (Passive Investment)

2018-02-12 sec.gov
    UNITED STATES     SECURITIES AND EXCHANGE COMMISSION     Washington, D.C. 20549         SCHEDULE 13G (Rule 13d-102)   Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1)*   INTELLIA THERAPUTICS, INC. (Name of Issuer) Common Stock, $0.0001 (Title of Class of Securities) 45826J105 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi

Mergers And Acquisitions: Is There A Pending Catalyst For Crispr Therapeutics?

2018-02-09 seekingalpha
Gilead is poised for the upcoming growth with various key catalysts such as NASH, HCV's expansion into China, and CAR-T. (78-0)

NTLA / Intellia Therapeutics, Inc. / Caribou Biosciences, Inc. - PRIMARY DOCUMENT (Passive Investment)

2018-02-06 sec.gov
13G     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G   Under the Securities Exchange Act of 1934   (Amendment No. 1)*   Intellia Therapeutics, Inc. (Name of Issuer)   Common Stock, par value $0.0001 per share (Title of Class of Securities)   45826J105 (CUSIP Number)   December 31, 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   ☐  Rule 13d-1(b)   ☐ 

NTLA / Intellia Therapeutics, Inc. / Caribou Biosciences, Inc. - PRIMARY DOCUMENT (Passive Investment)

2018-02-06 sec.gov
13G     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G   Under the Securities Exchange Act of 1934   (Amendment No. 1)*   Intellia Therapeutics, Inc. (Name of Issuer)   Common Stock, par value $0.0001 per share (Title of Class of Securities)   45826J105 (CUSIP Number)   December 31, 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   ☐  Rule 13d-1(b)   ☐ 

BioSci Rounds Report For Feb. 2, 2018

2018-02-04 seekingalpha
We expect Solid Biosciences (and other gene therapy/editing innovators) to deliver outstanding results in the long-haul. (97-0)

The 10 Best ETFs of January 2018

2018-02-02 investorplace
When compiling a list of the best ETFs of the month, the first twenty or so will undoubtedly be double- or triple-leveraged funds. But what happens when you exclude these funds from the list and focus solely on more standard exchange-traded funds? After all, these leveraged funds involve significantly higher risk and their default nature gives them an upper hand in performance … in a way, they’re “cheaters. (166-1)

NTLA / Intellia Therapeutics, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 2 (Activist Investment)

2018-01-29 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)*   INTELLIA THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 45826J105 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP V LLC OrbiMed Global Healthcare GP LLC   601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone:  (212) 739-6400 (Name, Address and Telephone Number of Person Authorized to Receive Notices


CUSIP: 45826J105